Patents Examined by James H. Reamer
  • Patent number: 7048951
    Abstract: A simple, biocompatible system and procedure for generating nitric oxide (NO) is described. A mixture of powdered sodium nitrite, ascorbic acid, and maleic acid (or another organic acid of adequate strength) immediately generates nitric oxide (NO) on treatment with water. To slow down the NO generation, one may prepare an ointment from a nonaqueous medium (petrolatum, Vaselineā„¢) and the three powdered ingredients, which on being applied topically on the skin will release NO as water permeates through this medium; alternatively, one may convert the aqueous sodium nitrite solution into a gel with hydroxyethylcellulose (or other gel-forming compound) and combine this gel with another gel obtained from aqueous ascorbic and maleic acids with hydroxyethylcellulose for topical application (on intact skin, burns intra-cavity, burns, intra-cavity, etc.).
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: May 23, 2006
    Assignee: Nioxx, LLC
    Inventors: William A. Seitz, Robert E. Garfield, Alexandru T. Balaban, Randall J. Stewart
  • Patent number: 6872749
    Abstract: The present invention relates to a method for supplying bioavailable methionine to a cow which comprises supplying to the cow an ester of methionine or methionine amide and/or an ester of the hydroxy analogue of methionine or a salt thereof.
    Type: Grant
    Filed: January 6, 2003
    Date of Patent: March 29, 2005
    Assignee: Adisseo Ireland Limited
    Inventors: Jean-Claude Robert, Robert Bennett, Georges Gros
  • Patent number: 6861431
    Abstract: Methods of modulating the activity of multidrug transporters are disclosed. The methods of modulating the activity of multidrug transporters use compounds that selectively increase or decrease the efflux capabilities of the multidrug transporter. The methods can be used therapeutically to enhance performance of therapeutic drugs, like chemotherapeutic drugs and antibiotics; to promote detoxification of cells and tissues; and to increase or decrease the efficacy of the blood-brain barrier or placental barrier.
    Type: Grant
    Filed: March 22, 2002
    Date of Patent: March 1, 2005
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Andrei Gudkov, Roman Kondratov
  • Patent number: 6806257
    Abstract: The present invention is directed to a method for inhibiting expression of either iNOS or COX-2, or both in mammals using flavone compounds, and pharmaceutically acceptable salts thereof. The present invention is also directed to a method of activating K+ channels in mammals; as well as methods for treating septic shock, for inhibiting expression of angiotensin converting enzyme, for treating or preventing aneurysms and for reducing inflammation and related pathological changes using these compounds. Presently preferred compounds are oroxylin A (5,7-dihydroxy-6-methoxy flavone) and wogonin (5,7-dihydroxy-8-methoxy flavone).
    Type: Grant
    Filed: October 20, 2000
    Date of Patent: October 19, 2004
    Assignee: Board of Trustees of Southern Illinois University
    Inventors: Tony Jer-Fu Lee, Chen Ling Ling Yang
  • Patent number: 6803369
    Abstract: A method of modulating the activity of a aberrant cell topoisomerase enzyme involving contacting the enzyme with a compound that inhibits enzyme-mediated cleavage of a polynucleotide substrate with which the enzyme is in complex. Pharmaceutical compositions containing such compounds may be used to treat neoplasias or to inhibit the growth of certain cancer cells. Screening methods can be employed to identify other compounds for these uses.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: October 12, 2004
    Assignees: SmithKline Beecham Corporation, SmithKlineBeecham p.l.c.
    Inventors: Symon G. Erskine, Michael Gwynn, Neil David Pearson, Edwina Imogen Wilding
  • Patent number: 6794410
    Abstract: The invention relates to the use of compound of Formula I in treating patients for the symptoms of multiple sclerosis.
    Type: Grant
    Filed: April 1, 2002
    Date of Patent: September 21, 2004
    Assignee: Aventis Pharmaceuticals Inc.
    Inventor: Joseph Wettstein
  • Patent number: 6780880
    Abstract: Fourier Transform Raman Spectroscopy (FT-Raman) determines the isomer ratio of chemical compositions.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: August 24, 2004
    Inventors: Robert R. Whittle, Frederick D. Sancilio, Grayson Walker Stowell
  • Patent number: 6777444
    Abstract: Use of nordihydroguaiaretic derivatives to suppress CDC-2 and survivin, stimulate apoptosis, and treat tumors.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: August 17, 2004
    Assignee: John Hopkins University
    Inventors: Ru Chih C. Huang, Jonathan D. Heller, Chih-Chuan Chang
  • Patent number: 6777445
    Abstract: The present invention relates to a method for treating a disease, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a fullerene. The diseases treated comprise bacterial and viral diseases such as those cause by Gram positive and Gram negative bacteria, Dengue 2 virus and viral encephalitis. The fullerene is administered in vivo in an amount of about 0.001 to about 100 mg/kg of body weight of the subject.
    Type: Grant
    Filed: October 17, 2001
    Date of Patent: August 17, 2004
    Assignee: National Health Research Institute
    Inventors: Huan-Yao Lei, Chen-Kung Chou, Tien-Yau Luh
  • Patent number: 6767925
    Abstract: A sprayable analgesic composition containing an analgesic which is absorbed into the bloodstream through the buccal mucosa and a pharmacologically acceptable liquid carrier.
    Type: Grant
    Filed: November 1, 1999
    Date of Patent: July 27, 2004
    Inventor: Joseph A. Deihl
  • Patent number: 6765010
    Abstract: The invention generally relates to compositions and methods with tramadol and an opioid antagonist to enhance analgesic potency and/or attenuate one or more adverse effects of tramadol, including adverse side effect(s) in humans such as nausea, vomiting, dizziness, headache, sedation (somnolence) or pruritis. This invention relates to compositions and methods for selectively enhancing the analgesic potency of tramadol and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects associated with the administration of tramadol. The methods of the present invention comprise administering to a subject an analgesic or subanalgesic amount of tramadol and an amount of excitatory opioid receptor antagonist such as naltrexone or nalmefene effective to enhance the analgesic potency of tramadol and attenuate the anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects of tramadol.
    Type: Grant
    Filed: March 12, 2002
    Date of Patent: July 20, 2004
    Assignees: Pain Therapeutics, Inc., Albert Einstein College of Medicine of Yeshiva University
    Inventors: Stanley M. Crain, Ke-Fei Shen, Barry Sherman, Mary Remien, Remi Barbier, Nadav Friedmann
  • Patent number: 6756399
    Abstract: The present invention provides a method for treating and preventing an epithelial cell-derived cancer in a subject in need thereof, comprising administering to the subject an amount of a 5-lipoxygenase inhibitor and PPAR ligand or derivatives thereof, effective to treat or prevent the epithelial cell-derived cancer. Also encompassed by the invention are inhibitors of enzymes that metabolize arachidonic acid.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: June 29, 2004
    Assignees: The United States of America as represented by the Department of Health and Human Services, The United States of America as represented by the Secretary of the Army
    Inventors: James L. Mulshine, Marti Jett
  • Patent number: 6747020
    Abstract: Methods of using eplerenone, an angiotensin converting enzyme inhibitor and optionally a diuretic are described for treatment of heart failure and hypertension.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: June 8, 2004
    Assignee: Pharmacia Corporation
    Inventors: Alfonzo T. Perez, Debra J. Asner, Richard J. LaChapelle, John C. Alexander, Barbara Roniker
  • Patent number: 6743806
    Abstract: A new active oxygen scavenger which comprises as an active ingredient a tetrazolylalkoxy-dihydrocarbostyril compound of the formula (I): wherein R is cycloalkyl group, A is lower alkylene group, and the bond between 3- and 4-positions of the carbostyril nucleus is single bond or double bond, or a salt thereof, and an agent for the prevention or treatment of an acute cerebral infarction comprising the same active ingredient.
    Type: Grant
    Filed: April 23, 2003
    Date of Patent: June 1, 2004
    Assignee: Otsuka Pharmaceutical Company, Limited
    Inventor: Ki Whan Hong
  • Patent number: 6743824
    Abstract: The present invention is directed to methods for alleviating the symptoms associated with peripheral neuropathy. The neuropathy may be the result of a genetically inherited condition, systemic disease or exposure to a toxic agent. A reduction or elimination of symptoms is obtained by administering the drug selegiline. The invention is also directed to a method for treating patients with cancer by administering a chemotherapeutic agent known to have a toxic affect on peripheral nerves together with selegiline.
    Type: Grant
    Filed: March 19, 2003
    Date of Patent: June 1, 2004
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventor: George Bobotas
  • Patent number: 6740668
    Abstract: The instant invention provides compositions and methods for modeling post-Amadori AGE formation and the identification and characterization of effective inhibitors of post-Amadori AGE formation, and such identified inhibitor compositions. The instant invention also teaches methods to treat or prevent diabetes associated hyperlipidemia, cellular redox imbalances, hypercholesterolemia, hypertriglyceridemia, and atherosclerosis, comprising administering the compounds of the invention to a mammal in need thereof.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: May 25, 2004
    Assignees: Kansas University Medical Center, University of South Carolina
    Inventors: John W. Baynes, Suzanne R. Thorpe, Thorsten P. Degenhardt, Raja G. Khalifah, Billy G. Hudson, Nathan Alderson
  • Patent number: 6740680
    Abstract: The present invention provides novel pharmaceutical compositions and methods of treatment that utilize or comprise tetrac and/or another thyromimetic compound. The pharmaceutical compositions of the invention are capable of suppressing TSH secretion without inhibiting the pituitary specific monodeiodinase type II and while reducing or avoiding the thyromimetic stimulation of peripheral tissues compared to equivalent TSH-suppressive doses of L-thyroxine (T4). The pharmaceutical compositions of the invention are particularly useful for treating patients suffering from malignancy or abnormal growth of the thyroid and for preventing growth of residual thyroid tissue post thyroidectomy.
    Type: Grant
    Filed: May 9, 2002
    Date of Patent: May 25, 2004
    Assignee: Becton Pharma, Inc.
    Inventors: Elliot Danforth, Jr., Albert Burger
  • Patent number: 6730686
    Abstract: The instant invention provides compositions and methods for modeling post-Amadori AGE formation and the identification and characterization of effective inhibitors of post-Amadori AGE formation, and such identified inhibitor compositions. The instant invention also teaches new methods to treat or prevent oxidative modification of proteins, including low density lipoproteins, to treat or prevent lipid peroxidation, and to treat or prevent atherosclerosis, comprising administering an amount effective of one of the compounds of the invention to treat or prevent the disorder.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: May 4, 2004
    Assignees: Kansas University Medical Center, University of South Carolina
    Inventors: John W. Baynes, Joelle Onorato, Suzanne Thorpe, Raja Khalifah, Billy G. Hudson
  • Patent number: 6730699
    Abstract: Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.
    Type: Grant
    Filed: November 20, 2002
    Date of Patent: May 4, 2004
    Assignee: PG-TXL Company, L.P.
    Inventors: Chun Li, Sidney Wallace, Dong-Fang Yu, David Yang
  • Patent number: 6730202
    Abstract: In a method for controlling sample introduction in microcolumn separation techniques, more particularly in capillary electrophoresis (CRE), where a sample is injected as a sample plug into a sampling device which comprises at least a channel for the electrolyte buffer and a supply and drain channel for the sample. The supply and drain channels discharge into the electrolyte channel at respective supply and drain ports. The distance between the supply port and the drain port geometrically defines a sample volume. The injection of the sample plug into the electrolyte channel is accomplished electrokinetically by applying an electric field across the supply and drain channels for a time at least long enough that the sample component having the lowest electrophoretic mobility is contained within the geometrically defined volume. The supply and drain channels each are inclined to the electrolyte channel. Means are provided for electrokinetically injecting the sample into the sample volume.
    Type: Grant
    Filed: February 9, 2001
    Date of Patent: May 4, 2004
    Assignee: Zeptosens AG
    Inventors: Andreas Manz, D. Jed Harrison, Carlo S. Effenhauser